Clinical Trial Update: A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) [Phase 2]

View source ↗

Summary

A Phase 2 randomized, placebo-controlled trial of serlopitant (NK1 receptor antagonist) in prurigo nodularis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Serlopitant (serlopitant)

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Prurigo Nodularis | Phase 2 | Status: COMPLETED | Results posted: 2021-02-02